A second global pivotal trial will test iza-bren in the same NSCLC setting where patri-dxd failed.
ApexOnco Front Page
Recent articles
If Pfizer hands back the estrogen receptor degrader, Arvinas will seek a new partner.
Genmab’s remarkably bold acquisition raises more questions about Sutro, a key FRα rival of ProfoundBio.
The group will need to wait for more data with its neoantigen immunotherapy Granite, but cash is running short.
A roundup of the first quarter's key oncology drug approvals and rejections.
A $44m up-front for the tumour-activated IL-12 XTX301 will help keep Xilio going until 2025.
The latest first-in-human study initiations will be of interest to followers of D2M Therapeutics, Nested and Volastra.
The takeover of AnHeart centres on advancing the latter’s targeted lung cancer project taletrectinib.